Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Public ClinicalTrials.gov record NCT02952898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.
Study identification
- NCT ID
- NCT02952898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 665 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 26, 2016
- Primary completion
- Jul 10, 2017
- Completion
- Sep 5, 2017
- Last update posted
- Jan 6, 2020
2016 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 07 | Fort Smith | Arkansas | 72916 | — |
| Site 14 | San Diego | California | 92117 | — |
| Site 24 | San Ramon | California | 94582 | — |
| Site 22 | Clearwater | Florida | 33756 | — |
| Site 01 | North Miami Beach | Florida | 33162 | — |
| Site 27 | Ocala | Florida | 34471 | — |
| Site 12 | Tampa | Florida | 33609 | — |
| Site 05 | Carmel | Indiana | 46032 | — |
| Site 02 | Plainfield | Indiana | 46168 | — |
| Site 25 | Saint Joseph | Missouri | 64506 | — |
| Site 21 | Albuquerque | New Mexico | 87106 | — |
| Site 03 | Warwick | Rhode Island | 02886 | — |
| Site 26 | Anderson | South Carolina | 29621 | — |
| Site 04 | Greenville | South Carolina | 29607 | — |
| Site 28 | Norfolk | Virginia | 23507 | — |
| Site 10 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02952898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2020 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02952898 live on ClinicalTrials.gov.